Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C156172
http://purl.obolibrary.org/obo/NCIT_C156172
|
|---|---|
| Preferred Name | Vulinacimab |
| Definitions |
A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types. |
|---|---|
| prefLabel | Vulinacimab
|
| label | Vulinacimab
|
| NCI_META_CUI | CL563001
|
| PDQ_Closed_Trial_Search_ID | 795367
|
| code | C156172
|
| prefixIRI | NCIT:C156172
|
| in_subset | |
| Preferred_Name | Vulinacimab
|
| FDA_UNII_Code | SA09JNQ24D
|
| Contributing_Source | FDA
|
| Maps_To |
Anti-VEGFR2 Monoclonal Antibody HLX06
Vulinacimab
|
| CAS_Registry | 2250342-36-8
|
| NCI_Drug_Dictionary_ID | 795367
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 795367
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |